Fall 2013
Although statin therapy is a cornerstone of cardiovascular disease prevention, and although it achieves the largest reduction of low-density lipoprotein (LDLC), 1 and has one of the safest overall side-effect profiles among lipid-lowering medications, some patients are unable to tolerate statins... more
The National Heart, Lung and Blood Institute (NHLBI) recommends universal pediatric lipid screening to identify and treat children with serious genetic dyslipidemias.1 Primary care providers should certainly identify children who will be candidates for statin therapy. One in 500 people are... more
Studies specifically designed to evaluate prevalence of statin-related myalgia have shown that approximately 22% of patients on statins have some degree of musculoskeletal pain.1 As clinicians, we know it is difficult for patients to discern between pain related to statin intolerance and that... more


.png)







